Kazia Therapeutics Shares Are Jumping Today: Successful Study For Brain Cancer Treatment
Kazia Therapeutics Limited KZIA released results on Wednesday from the GBM-AGILE Phase 2/3 study that included an evaluation of paxalisib versus standard of care (SOC) for patients with glioblastoma, a type of brain cancer. Shares are trading higher …